Publication | Open Access

Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial

Drug SafetyHepatologyDecompensated CirrhosisLiver PhysiologyPharmacologyHepatotoxicityPharmacotherapyLiver DiseaseDifferent DosesMedicineDrug-induced Liver Injury